Messenger ribonucleic acid encoding analogs of p53 protein, and medical uses thereof
A polyribonucleotide encoding a p53 analog with specific variations, encapsulated in lipid nanoparticles, addresses the challenge of restoring p53 function in cancers with mutations, effectively inhibiting cancer cell growth and treating ovarian, liver, and lung cancer.
Patent Information
- Application Number
- PCT/KR2026/005903
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-04-15
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing cancer therapies struggle to effectively restore the function of p53 protein, particularly in cancers with p53 mutations, leading to chemotherapy and radiation resistance, and there is a need for an analog of p53 that promotes apoptosis in cancer cells and offers stability.
A polyribonucleotide encoding a p53 analog with specific amino acid sequence variations is developed, encapsulated in lipid nanoparticles, which are administered to enhance stability and inhibit cancer cell growth.
The p53 analog polyribonucleotide effectively inhibits the growth of cancer cells, particularly those with p53 mutations, showing improved stability and transcription efficiency, and is effective in treating cancers such as ovarian, liver, and lung cancer.
Smart Images

Figure KR2026005903_12112026_PF_FP_ABST
Abstract
Description
Messenger ribonucleic acid encoding an analog of the p53 protein and its medical uses
[0001] The present invention relates to the treatment and prevention of cancer. Specifically, the present invention relates to mRNA encoding an analog of the p53 protein and a method for delivering it into the body.
[0002] p53 is a protein encoded by the TP53 gene in humans and has even earned the nickname "guardian of the genome" because it plays a crucial role in preventing cancer as a tumor suppressor in the cell cycle of multicellular organisms. p53 is known to cope with genotoxic and oncogenic stress by inducing cell cycle arrest or apoptosis, and is involved in various intracellular and extracellular stress environments such as DNA damage, activation of oncogenes, nutrient deficiency, and oxygen deficiency. Loss of p53 activity is one of the major characteristics of cancer and is known to occur in more than half of human primary tumors.
[0003] p53 mutations resulting in the loss of p53 activity frequently occur in tumor cells and are associated with cancer progression and the development of resistance to chemotherapy and radiation therapy. In vitro and in vivo preclinical studies have shown that restoring wild-type p53 function can induce apoptosis in cancer cells.
[0004] Therefore, there is growing interest in therapies that restore the function of p53 in cancer, particularly in cancers with a p53 mutation genetic environment, or further enable p53 to have activity superior to that of the natural p53 state.
[0005] One of the technical challenges of the present invention is to provide an analog of p53 that promotes apoptosis in cancer cells and offers excellent stability. More specifically, the challenge is to provide an isolated polyribonucleotide or messenger ribonucleic acid (mRNA) encoding such a p53 analog.
[0006] Another technical problem of the present invention is to provide a composition comprising a polyribonucleotide or messenger ribonucleic acid of such p53 analog as an active ingredient, said polyribonucleotide or messenger ribonucleic acid, which causes said polyribonucleotide or messenger ribonucleic acid to be expressed when administered into the body.
[0007] Another technical problem of the present invention is to provide a composition for preventing or treating cancer in an individual using a polyribonucleotide or messenger ribonucleic acid of such p53 analogues.
[0008] Another technical problem of the present invention is to provide a method for using polyribonucleotides or mRNA, comprising the step of introducing such p53 analogues, polyribonucleotides, or messenger ribonucleic acid into a host cell.
[0009] To solve the aforementioned technical problem, the present invention provides an analog of p53. In one aspect, the present invention discloses a polyribonucleotide encoding a p53 analog. This polyribonucleotide comprises at least one 5' untranslated region, at least one 3' untranslated region, an open decoding frame operably connected to the 5' untranslated region and the 3' untranslated region and encoding a p53 analog polypeptide, and a polyadenine tail located at the 3' end direction of the 3' untranslated region. The amino acid sequence of the p53 analog polypeptide is a sequence in which one or more variant elements selected from the group consisting of the following variant elements (A) to (G) are added to the natural p53 amino acid sequence.
[0010] (A) S46E;
[0011] (B) S15E, S20E, S46E;
[0012] (C) G325E, F341L, L344I, Q354M;
[0013] (D) E17G, D21Y, W23G, N29K, N30L;
[0014] (E) L14_S15insD, T18del, S20A, D21E, W23_K24insE, L25N;
[0015] (F) E180R, R181E; and
[0016] (G) E180K, R181D.
[0017] In one embodiment, the polyribonucleotide p53 analog polypeptide of the present invention is a sequence having a variation of any set of variations selected from [1] to
[0012] in the natural p53 amino acid sequence.
[0018] [1] S46E,
[0019] [2] S15E, S20E, S46E,
[0020] [3] G325E, F341L, L344I, Q354M,
[0021] [4] E17G, D21Y, W23G, N29K, N30L,
[0022] [5] E17G, D21Y, W23G, N29K, N30L, G325E, F341L, L344I, Q354M,
[0023] [6] L14_S15insD, T18del, S20A, D21E, W23_K24insE, L25N,
[0024] [7] L14_S15insD, T18del, S20A, D21E, W23_K24insE, L25N, G325E, F341L, L344I, Q354M,
[0025] [8] E180R, R181E,
[0026] [9] E180K, R181D,
[0027]
[0010] E180K, R181D, G325E, F341L, L344I, Q354M,
[0028]
[0011] E17G, D21Y, W23G, N29K, N30L, E180K, R181D and
[0029]
[0012] E180R, R181E, G325E, F341L, L344I, Q354M.
[0030] In another aspect of the present invention, a composition is provided in which the aforementioned polyribonucleotide is encapsulated within lipid nanoparticles. In this composition, the lipid nanoparticles have a size of 200 nm or less and contain cationic lipids, sterols, phospholipids, and polyethylene glycol-modified lipids. In one embodiment, this composition is a pharmaceutical composition for the prevention or treatment of cancer. In one specific embodiment, the cancer is ovarian cancer, liver cancer, gastric cancer, or lung cancer. More specifically, the ovarian cancer, liver cancer, gastric cancer, or lung cancer is a cancer having a p53 mutation that reduces the activity of p53 in cancer cells.
[0031] The p53 analog polyribonucleotide of the present invention is relatively stable when administered into the body and can inhibit the growth of cancer cells. Furthermore, the p53 analog polyribonucleotide of the present invention is a ribonucleic acid sequence with excellent in vitro transcription efficiency. The p53 analog polyribonucleotide of the present invention can be used for the treatment or prevention of cancer, particularly cancer caused by p53 mutations. More specifically, the p53 analog polyribonucleotide of the present invention can be used for the treatment and prevention of ovarian cancer, liver cancer, gastric cancer, or lung cancer.
[0032] Figure 1 shows pUC57-Kan, a template vector for expressing each p53 protein R This is a schematic diagram of p53.
[0033] Figure 2a is a graph showing the degree of inhibition of cell growth when mRNA of natural p53 or a p53 analog is introduced into ovarian cancer cell line ES-2 carrying a p53 point mutation.
[0034] Figure 2b is a graph showing the degree of inhibition of cell growth when mRNA of natural p53 or a p53 analog is introduced into lung cancer cell line H1373 carrying a p53 point mutation.
[0035] Figures 3a to 3c show the tumor size (Figure 3a), change in mouse body weight (Figure 3b), and tumor growth inhibitory ability (Figure 3c) on day 21 after administration in an animal model of ovarian cancer in which a tumor was induced by xenografting an ES-2 cell line into a nude mouse.
[0036] Figure 4 is a Western blot image showing the proportion of p53 tetramers formed in the cells after injecting mRNA of natural p53 or p53 analog 3 into cell line H1299 with a null p53 genotype, isolating proteins from the cells, and cross-linking some of them. In Figure 4, - and + indicate whether 0.1% glutaraldehyde cross-linking was performed, WT indicates the natural p53 mRNA cell injection group, and 3 indicates the p53 analog 3 mRNA cell injection group.
[0037] Figure 5 is a graph showing the quantification of the binding strength of the extract to the intrinsic recognition oligodeoxyribonucleotide sequence of p53 using enzyme-linked immunosorbent assay (ELISA), after H1299 cells were inoculated with mRNA of natural p53 or a p53 analog and the nuclei of the cells were extracted. In Figure 5, WT indicates the natural p53 mRNA inoculation group, and #3 indicates the p53 analog 3 mRNA inoculation group. In Figure 5 ***The notation indicates that the measurement results showed a statistically significant difference (p<0.001) compared to the natural p53 mRNA cell inflow group when statistically tested using one-way ANOVA.
[0038] Figure 6a is a graph showing the degree of inhibition of cell growth when the p53 analog mRNA of the present invention is introduced into the hepatocellular carcinoma cell line Huh7, which has a p53 point mutation.
[0039] Figure 6b is a graph showing the degree of inhibition of cell growth when the p53 analog mRNA of the present invention is introduced into Hep3B, a hepatocellular carcinoma cell line completely deficient in p53.
[0040] Figure 6c is a graph showing the degree of inhibition of cell growth when the p53 analog mRNA of the present invention is introduced into NUGC-3, a gastric adenocarcinoma cell line carrying a p53 point mutation.
[0041] Figure 6d is a graph showing the degree of inhibition of cell growth when the p53 analog mRNA of the present invention is introduced into HCC827, a lung adenocarcinoma cell line with a p53 point mutation and a deletion in EGFR gene exon 19.
[0042] Figure 6e is a graph showing the degree of inhibition of cell growth when the p53 analog mRNA of the present invention is introduced into lung adenocarcinoma cell line H1975 having p53 point mutations and EGFR point mutations.
[0043] Embodiments of the present invention will be described in detail below. Prior to this, terms and words used in this specification and claims should not be interpreted as being limited to their ordinary or dictionary meanings. Instead, based on the principle that the inventor can appropriately define the concepts of terms to best describe his invention, they should be interpreted in a meaning and concept consistent with the technical spirit of the present invention.
[0044] Therefore, the embodiments described in this specification are merely examples presented for the purpose of helping to understand the invention and do not represent all technical ideas of the invention; thus, it should be understood that various equivalents and modifications that can replace them may exist at the time of filing this application.
[0045] Unless otherwise defined, all technical terms used in this invention are used in the sense generally understood by a person skilled in the art related to this invention. While preferred methods or samples are described herein, similar or equivalents are also included within the scope of this invention. Numerical values described herein are deemed to include the meaning of "approximately" unless explicitly stated otherwise. Numerical ranges indicated by the term "to" in this specification include ranges that include the values described before and after the term "to" as lower and upper limits, respectively.
[0046] In the specification of the present invention, the statement that two or more DNA sequence elements or two or more RNA sequence elements are "operably linked" to each other indicates that the relationship in which these two or more sequence elements are positioned allows these sequence elements to function in an expected manner. When the sequence elements are a regulatory sequence and a coding sequence, the statement that they are "operably linked" means that the regulatory sequence influences the expression of the coding sequence to which it is linked. Regulatory sequences include, for example, a promoter; a translation leader sequence; 5' and 3' non-translation regions; an intron; an enhancer; a stem-loop structure; a repressor binding sequence; a termination sequence; a polyadenine tail, etc. The regulatory sequence may be positioned in the 5' or 3' direction with respect to the coding sequence operably linked to the regulatory sequence, and in typical cases, they are immediately connected, but not necessarily, and a nucleotide residue may be interposed between the operably linked regulatory sequence and the coding sequence.
[0047] In the specification of the present invention, "5' untranslated region (5' UTR)" refers to a region of mRNA that is directly upstream (i.e., in the 5' direction) from the first codon of the messenger ribonucleic acid (mRNA) transcript that is translated by the ribosome, that is, a start codon that does not code for a polypeptide.
[0048] In the specification of the present invention, "3' untranslated region (3' UTR)" refers to a region of mRNA located directly downstream (i.e., in the 3' direction) from a stop codon that does not code for a polypeptide, that is, a codon of the mRNA transcript that signals translation termination.
[0049] In this specification, "open reading frame (ORF)" or "sequence encoding a polypeptide" refers to a continuous region of DNA encoding a polypeptide that starts with a start codon, e.g., a methionine codon (ATG), ends with a stop codon, e.g., TAA, TAG, or TGA.
[0050] In this specification, "polyadenine tail" refers to a region of mRNA located downstream from a 3' UTR, for example, directly downstream, containing a plurality of consecutive adenine nucleotides. A polyadenine tail may contain 1,000, 500, 400, or 300 or fewer adenine nucleotides. For example, such a polyadenine tail may contain 10 to 300 adenine nucleotides. For example, such polyadenine tails may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300 adenine nucleotides. The polyadenine tails may contain, for example, 50 to 250 adenine nucleotides. In a living organism, such as a cell or organism, the polyadenine tails may serve to protect mRNA from attack by enzymes, for example, enzymes in the cytoplasm, and to assist in transcription termination, the export of mRNA from the nucleus, and translation.
[0051] In this specification, unless otherwise mentioned regarding the position of the nucleotide sequence, it indicates that it is connected or located from the 5' end to the 3' end.
[0052] In the specification of the present invention, the term “lipid nanoparticle” refers to a particle having at least one nanometer-scale (e.g., 1 to 1,000 nm) dimension comprising a cationic lipid. In some embodiments, lipid nanoparticles are included in a formulation that can be used to deliver an activator or therapeutic agent, such as a nucleic acid (e.g., mRNA), to a target site (e.g., a cell, tissue, organ, tumor, etc.). In some embodiments, the lipid nanoparticles of the present invention comprise a nucleic acid. These lipid nanoparticles typically comprise cationic lipids, phospholipids, cholesterol, and polymer-bound lipids to which polymers such as polyethylene glycol are bound. The lipid nanoparticles may encapsulate the nucleic acid, which is the activator, within an internal space surrounded by the constituent lipids of the lipid nanoparticles, thereby protecting the nucleic acid from enzymatic degradation or other undesirable effects (e.g., adverse immune response) induced by mechanisms of the host organism or cell.
[0053] The present invention provides an analog of p53 that has excellent relative stability and can inhibit the growth of cancer cells.
[0054] Human natural p53 is a protein composed of 393 amino acids (Sequence No. 1) and includes a first transactivation domain, a second transactivation domain, a proline-rich domain, a DNA binding domain, a tetramerization domain, and a C-terminal regulatory domain in the direction from the N-terminus to the C-terminus. In the present invention, when referred to as an analog of p53, it refers to a protein containing at least one variant with respect to the natural p53 sequence. Here, a variant refers to a substitution, deletion, and / or insertion of amino acids in the amino acid sequence of natural p53. In this specification, such variants are indicated using a conventional single-letter amino acid notation, a residue position number based on the natural p53 sequence, and an abbreviation indicating the type of variant. For example, a substitution variant in which serine at the 46th position based on the natural p53 sequence is changed to glutamic acid is indicated as S46E. For example, an insertion variant in which aspartic acid is added between the leucine residue at the 14th position and the serine residue at the 15th position based on the natural p53 sequence is denoted as L14_S15insD. For example, a deletion variant in which a threonine residue at the 18th position based on the natural p53 sequence is removed is denoted as T18del.
[0055] In one embodiment, a variation of p53 capable of constituting a p53 analog according to the present invention is a variation present in the portion corresponding to the 14th to 47th amino acid residues based on the sequence of natural p53 within the first trans-activating region and the second trans-activating region, and is a variation having enhanced transcriptional activity compared to natural p53. In another embodiment, a variation of p53 capable of constituting a p53 analog is a variation present in the portion corresponding to the 14th to 47th amino acid residues based on the sequence of natural p53 within the first trans-activating region and the second trans-activating region, and is a variation having reduced binding activity to MDM2 compared to natural p53. In another embodiment, another variant of p53 capable of constituting a p53 analog is a variant present in the DNA binding region of p53 corresponding to amino acid residues 174 through 184 based on the sequence of natural p53, which is a variant that enhances the DNA binding cooperativity of p53 compared to natural p53. In yet another embodiment, another variant of p53 capable of constituting a p53 analog is a variant present in the tetramerization region of p53 corresponding to amino acid residues 324 through 356 based on the sequence of natural p53, which is a variant that promotes tetramerization compared to natural p53.
[0056] The p53 analog according to the present invention may be a protein comprising any one of the p53 variants capable of constituting the aforementioned p53 analog in a natural p53 sequence. Additionally, the p53 analog according to the present invention may be a protein having a sequence comprising two or more p53 variants capable of constituting the aforementioned p53 analog in a natural p53 sequence.
[0057] In one specific embodiment, the variant present in the region corresponding to the 14th to 47th amino acid residues based on the sequence of natural p53, which has enhanced transcriptional activity compared to natural p53, is S46E. In another specific embodiment, the variant present in the region corresponding to the 14th to 47th amino acid residues based on the sequence of natural p53, which has reduced binding activity to MDM2 compared to natural p53, is a set of variants S15E, S20E, and S46E. In yet another specific embodiment, the variant present in the region corresponding to the 14th to 47th amino acid residues based on the sequence of natural p53, which has reduced binding activity to MDM2 compared to natural p53, is a set of variants E17G, D21Y, W23G, N29K, and N30L. In one other specific embodiment, the variants present in the region corresponding to the 14th to 47th amino acid residues of the natural form p53 sequence, which result in reduced binding activity to MDM2 compared to the natural form p53, are the set of variants L14_S15insD, T18del, S20A, D21E, W23_K24insE, and L25N. In another specific embodiment, the variants present in the region corresponding to the 174th to 184th amino acid residues of the natural form p53 sequence, which result in improved DNA binding cooperability of p53 compared to the natural form p53, are the set of variants E180R and R181E. In another specific embodiment, the variants present in the region corresponding to the 174th to 184th amino acid residues of the natural form p53 sequence, which improve the DNA binding cooperability of p53 compared to the natural form p53, are the set of variants E180K and R181D.In one other specific embodiment, the variants present in the portion corresponding to the 324th to 356th amino acid residues of the natural form p53, which promote tetramerization compared to the natural form p53, are a set of variants G325E, F341L, L344I and Q354M.
[0058] In one aspect of the present invention, a polyribonucleotide encoding the aforementioned p53 analog is disclosed. The polyribonucleotide comprises at least one 5' untranslated region, at least one 3' untranslated region, an open decoding frame operably connected to the 5' untranslated region and the 3' untranslated region and encoding a p53 analog polypeptide, and a polyadenine tail located at the 3' end direction of the 3' untranslated region.
[0059] In this case, the amino acid sequence of the above p53 analog polypeptide is a sequence in which one or more variant elements selected from the group consisting of the following variant elements (A) to (G) are added to the natural p53 amino acid sequence.
[0060] (A) S46E;
[0061] (B) S15E, S20E, S46E;
[0062] (C) G325E, F341L, L344I, Q354M;
[0063] (D) E17G, D21Y, W23G, N29K, N30L;
[0064] (E) L14_S15insD, T18del, S20A, D21E, W23_K24insE, L25N;
[0065] (F) E180R, R181E; and
[0066] (G) E180K, R181D.
[0067] In one embodiment, the amino acid sequence of the p53 analog polypeptide comprises any combination of two or more of the variant elements of (A) to (F).
[0068] The polyribonucleotides encoding the p53 analog of the present invention encompass all possible degenerate sequences of polyribonucleotides encoding the same analog amino acid sequence. For example, these polyribonucleotides encoding the p53 analog include not only ribonucleotide sequences that are codon-optimized for in vitro transcription while encoding the corresponding p53 analog polypeptide, but also all other ribonucleotide sequences that encode the same polypeptide but are not codon-optimized. Furthermore, the polyribonucleotides encoding the p53 analog polypeptide include not only polyribonucleotides composed of ribonucleotides containing only natural nitrogen bases, but also polyribonucleotides containing modified ribonucleotides containing non-natural nitrogen bases that can encode the same polypeptide.
[0069] In one specific embodiment, the polyribonucleotide of the present invention is a sequence in which the amino acid sequence of the p53 analog polypeptide has a variation of any one set of variations selected from [1] to
[0012] of the natural p53 amino acid sequence.
[0070] [1] S46E;
[0071] [2] S15E, S20E, S46E;
[0072] [3] G325E, F341L, L344I, Q354M;
[0073] [4] E17G, D21Y, W23G, N29K, N30L;
[0074] [5] E17G, D21Y, W23G, N29K, N30L, G325E, F341L, L344I, Q354M;
[0075] [6] L14_S15insD, T18del, S20A, D21E, W23_K24insE, L25N;
[0076] [7] L14_S15insD, T18del, S20A, D21E, W23_K24insE, L25N, G325E, F341L, L344I, Q354M;
[0077] [8] E180R, R181E;
[0078] [9] E180K, R181D;
[0079]
[0010] E180K, R181D, G325E, F341L, L344I, Q354M;
[0080]
[0011] E17G, D21Y, W23G, N29K, N30L,E180K, R181D; and
[0081]
[0012] E180R, R181E, G325E, F341L, L344I, Q354M.
[0082] In the polyribonucleotide of the present invention, the 5' untranslated region may be the 5' untranslated region of natural p53 or any 5' untranslated region of non-natural p53 provided that it is operably linked to a p53 analog ORF.
[0083] In one embodiment, the 5' untranslated region is a non-natural sequence that does not form a secondary structure. Such a 5' UTR has activity that increases the gene yield compared to a natural 5' UTR sequence.
[0084] In one specific embodiment, the 5' non-translated region is any one sequence selected from the group consisting of sequence number 44 to sequence number 52.
[0085] In the polyribonucleotide of the present invention, the 3' non-translating region may be selected as a sequence similar to a natural 3' non-translating region that has excellent activity for increasing gene yield, for example, to synergistically increase the mRNA production yield when combined with a 5' non-translating region. For example, the 3' UTR may be selected as a sequence encoding a p53 analog polypeptide and to synergistically increase the RNA production yield when combined with the aforementioned 5' UTR. The mRNA may exhibit an increased transcription or translation yield compared to the case containing a C3 5' UTR.
[0086] In one specific embodiment, the 3' non-translated region is any one sequence selected from the group consisting of sequence numbers 53 to 60.
[0087] In one specific embodiment, the polyribonucleotide of the present invention is a sequence formed by combining a 5' UTR of any one of sequences 44 to 52 and a 3' UTR of any one of sequences 53 to 60.
[0088] The above 5'UTR or the above 3' UTR may have an activity that increases translation yield and / or stability of the RNA compared to when a natural 5' UTR and / or a natural 3' UTR is used.
[0089] In the most specific embodiment, the polyribonucleotide of the present invention is any one polyribonucleotide sequence selected from the group consisting of SEQ ID NOs 32 to 43.
[0090] In the polyribonucleotides of the present invention, the polyribonucleotide sequences also include sequences containing one or more modified nucleotides that replace natural nucleotides. For example, some of the modified nucleotides that can be used in the polyribonucleotides of the present invention include pseudouridine, 1-methylpseudouridine, 5-methyluridine (m5U), 5-methoxyuridine (mo5U), and 2-thiouridine (s2U), which can replace uridine residues.
[0091] The polyribonucleotides of the present invention include not only polyribonucleotides of the aforementioned nucleotide sequences, but also polyribonucleotides in which at least some of the uridine residues of these nucleotide sequences are replaced with modified nucleotides selected from the group consisting of pseudouridine, 1-methylpseudouridine, 5-methyluridine (m5U), 5-methoxyuridine (mo5U), and 2-thiouridine (s2U).
[0092] In another specific embodiment, the polyribonucleotide of the present invention is any one polyribonucleotide sequence selected from the group consisting of SEQ ID NOs 32 to 43, wherein at least a portion of the uridine residues in the polyribonucleotide sequence is replaced with a modified nucleotide selected from the group consisting of pseudouridine, 1-methylpseudouridine, 5-methyluridine (m5U), 5-methoxyuridine (mo5U), and 2-thiouridine (s2U).
[0093] In one embodiment, the polyribonucleotide encoding the p53 analog of the present invention is prepared from a DNA template by in vitro transcription.
[0094] The terms "in vitro transcription" or "RNA in vitro transcription" refer to the process of synthesizing RNA, including mRNA, in a cell-free system, i.e., in vitro. Cloning vector DNA, including plasmid DNA vectors, can be applied as a template for the generation of RNA transcripts. These cloning vectors are also generally referred to as transcription vectors. RNA can be obtained by DNA-dependent in vitro transcription of a suitable DNA template. The DNA template may be a linearized plasmid DNA template. The promoter controlling RNA in vitro transcription may be any promoter for DNA-dependent RNA polymerase. The DNA-dependent RNA polymerase may be T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, or a combination thereof. The DNA template for RNA in vitro transcription can be obtained by cloning a nucleic acid and introducing it into a vector for RNA in vitro transcription. The DNA may contain cDNA corresponding to each RNA being transcribed in vitro. The vector for the above RNA in vitro transcription may be circular plasmid DNA. The above cDNA may be obtained by reverse transcription of mRNA or chemical synthesis.
[0095] The transcription vector may include a promoter, a nucleotide sequence encoding the 5'UTR, a sequence encoding a polypeptide, for example, an open reading frame (ORF), a nucleotide sequence encoding the 3'UTR, and a polyadenine tail. The transcription vector may also include a replication origin, for example, the E. coli replication origin ColE1 ori, a selection marker gene, or a combination thereof. The promoter may be a T7 promoter. The selection marker may be an antibiotic, for example, a kanamycin resistance enzyme.
[0096] The above-described in vitro transcription may include the step of introducing the transcription vector into a host cell, e.g., E. coli, to obtain a transformed host cell, and culturing the obtained host cell to proliferate the host cell containing plasmid DNA that serves as a template for mRNA. The above-described in vitro transcription may include the step of isolating the plasmid DNA from the proliferated host cell, e.g., E. coli. The step of isolating the plasmid DNA may include separating a cell layer from the culture and isolating the plasmid DNA from the cell. Separation of the cell layer may be achieved by centrifugation, separation, precipitation, or a combination thereof. Isolation of the plasmid DNA from the cell may be achieved by known methods, e.g., alkaline extraction, affinity chromatography, HPLC, electrophoresis, or a combination thereof. The method of obtaining the RNA may include the step of culturing the cell containing the DNA to produce an RNA transcript of the DNA.
[0097] The polyribonucleotide of the present invention may further include a “5’ cap” such as cap0, cap1, or cap2 in addition to the aforementioned 5’ untranslated region, 3’ untranslated region, an open decoding frame encoding a p53 analog polypeptide, and a polyadenine tail.
[0098] The term "5' cap" refers to a cap structure found at the 5' end of an mRNA molecule. The 5' cap is generally a 7-methylguanine ribonucleotide connected via a 5' triphosphate to the 5' position of the first nucleotide of the 5'-to-3' chain of the mRNA. In cap 0, the ribose of the first and second cap-proximal nucleotides of the mRNA both have an unmodified 2'-hydroxyl group and are hydroxyl groups. In cap 1, the ribose of the first and second cap-proximal nucleotides of the mRNA has a methoxyl group and an unmodified hydroxyl group, respectively. In cap 2, the ribose of the first and second cap-proximal nucleotides of the mRNA both have a modified 2' hydroxyl group to a methoxyl group. The 7-methylguanine ribonucleotide may be further modified. For example, modified 7-methylguanine ribonucleotide is 7-methylguanine 3'-methoxy(m 7 G(3'-OMe)) or 2'-hydroxyl and 3'-hydroxyl may be independently substituted with a sulfonyl-containing group selected from the group consisting of, for example, mesyl, esyl, tribril, tresyl, tosyl, brocyl, nosyl, and dansyl groups. The modified 7-methylguanine ribonucleotide substituted with a sulfonyl-containing group is, for example, 7-methylguanine 3'-mesyl(m 7 It may be G(3'-OMs). Most endogenous higher eukaryotic mRNAs, including mammalian mRNA such as human mRNA, contain cap 1 or cap 2. Cap 0, and other cap structures distinct from cap 1 and cap 2, may be immunogenic in mammals such as humans.
[0099] The above cap can be introduced co-transcriptionally with in vitro transcription. For example, a 5' cap or 5' cap analog can be introduced into the transcript at the initiation stage by transcribing a DNA template in vitro in the presence of the 5' cap or 5' cap analog. Additionally, the cap can be introduced into the RNA post-transcriptionally. The 5' cap or 5' cap analog can be introduced into the RNA post-transcriptionally by a capping enzyme, for example, a capping enzyme of the vaccinia virus. The 5' end sequence having the 5' cap structure formed is, for example, m 7 G(5')ppp(5')ApG, m 7 G(3'-OMe)(5')ppp(5')ApG, m 7 G(3'-OMe)(5')ppp(5')(2'-OMeA)pG, m 7 G(3'-OMs)(5')ppp(5')(2'-OMeA)pG or m 7 It may include G(5')ppp(5')(2'-OMeA)pG.
[0100] In another aspect of the present invention, a lipid nanoparticle composition containing mRNA that is a polyribonucleotide of a p53 analog is provided. This lipid nanoparticle composition may be intended to deliver mRNA or a p53 analog polypeptide expressed thereby to an individual.
[0101] The lipid nanoparticle composition of the present invention comprises lipid nanoparticles and mRNA contained within the lipid nanoparticles, wherein the mRNA is a polyribonucleotide encoding the aforementioned p53 analog polypeptide, and wherein the lipid nanoparticles have a size of 200 nm or less, and the lipid nanoparticles contain cationic lipids, sterols, phospholipids, and polyethylene glycol (PEG) modified lipids.
[0102] Methods for preparing compositions or formulations of lipid nanoparticles containing ribonucleic acid such as mRNA are known in the art and are therefore not described in detail here. The cationic lipids that can be used in the lipid nanoparticle compositions of the present invention are a category that includes lipids that have a permanent positive charge as quaternary ammonium salts and lipids that become protonated at low pH to acquire a positive charge. Some examples of cationic lipids that can be used in the lipid nanoparticle composition of the present invention include 1,2-di-o-octadecenyl-3-trimethylammoniumpropane (DOTMA), 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dimethyldioctadecylammonium bromide (DDAB), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (SM-102) and ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315). Some examples of phospholipids that can be used in the lipid nanoparticle composition of the present invention include 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), dioleoyl phosphatidylethanolamine (DOPE), and dipalmitoyl phosphatidylcholine (DPPC). Some examples of sterols that can be used in the lipid nanoparticle composition of the present invention include cholesterol. Some examples of polyethylene glycol-modified lipids that can be used in the lipid nanoparticle composition of the present invention include 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159), and polyethylene glycol dimethacrylate (PEG-DMA).
[0103] In one specific embodiment, the polyethylene glycol modified lipid is 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG2000-DMG), the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), the sterol is cholesterol, and the cationic lipid is the compound 1 below.
[0104] (Compound 1)
[0105]
[0106] In another specific embodiment, the polyethylene glycol modified lipid is compound 2 (ALC-0159) of the structure shown below, the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), the sterol is cholesterol, and the cationic lipid is compound 3 (ALC-0315) of the structure shown below.
[0107] (Compound 2)
[0108]
[0109] (Compound 3)
[0110]
[0111] In one specific embodiment, the lipid nanoparticle composition comprises 20 to 60 mol% cationic lipid, 5 to 25 mol% phospholipid, 25 to 55 mol% sterol, and 0.5 to 15 mol% polyethylene glycol modified lipid.
[0112] The lipid nanoparticle composition containing mRNA of a p53 analog of the present invention may be a pharmaceutical composition or one component thereof for preventing or treating cancer in an individual, comprising said mRNA as an active ingredient. This lipid nanoparticle composition may be intended to deliver the mRNA or the p53 analog polypeptide expressed thereby to an individual. said delivery may be intended to prevent or treat cancer in an individual.
[0113] In this pharmaceutical composition, the cancer may be a solid tumor, and in the most specific embodiment, the cancer may be ovarian cancer, liver cancer, stomach cancer, or lung cancer.
[0114] Additionally, in this pharmaceutical composition, the cancer may include a p53 mutation. Or, in this pharmaceutical composition, the cancer may be caused by a mutated p53. In a specific embodiment, the cancer is a cancer having a p53 mutation that reduces the activity of p53 in its cancer cells. Types of mutations that reduce activity include p53 point mutations, insertions, deletions, translocations, as well as p53 null mutations. The cancer may be one in which the cancer and / or its metastasis can be treated, reduced, inhibited, improved, and / or prevented by supplementing wild-type p53 or a functional fragment thereof. The composition may be intended to treat, reduce, inhibit, improve, and / or prevent cancer and / or its metastasis in an individual. The individual may be a mammal, including a human. The lipid nanoparticle composition containing mRNA of the p53 analog of the present invention is administered to an individual, and the RNA (e.g., mRNA) can be translated in vivo to produce a therapeutic polypeptide, namely the p53 analog of the present invention or a functional fragment thereof. The composition may be brought into contact with cells, tissues, or individuals in a "therapeutically effective amount" of the mRNA. The term "therapeutically effective amount" encompasses an amount that improves overall treatment, an amount that alleviates or avoids the cause of symptoms or disease or pathological conditions, and an amount that enhances the therapeutic efficacy of other therapeutic agents. The therapeutically effective amount may be determined based on the target tissue, target cell, means of administration, physical properties of the RNA (e.g., size and degree of modified nucleoside content), and other components of the composition. The composition may be administered intramuscularly, subcutaneously, intradermally, nasally, or into the lungs.
[0115] The above pharmaceutical composition may comprise one or more pharmaceutically acceptable carriers or excipients. The mRNA of the p53 analog, which is the active ingredient in the composition, may be encapsulated within lipid nanoparticles in a form formulated or complexed with said carrier or excipient. said carrier or excipient may be known in the art. The relative amounts of the active ingredient, pharmaceutically acceptable carrier, excipient, and / or other additional ingredients included in the composition may vary depending on the identity, size and / or condition of the subject to be treated and the route of administration. For example, the composition may comprise 0.1% to 100%, for example, 0.5% to 50%, 1.0% to 30%, 5.0% to 80%, or 80% (w / w) or more of the active ingredient.
[0116] In another aspect of the present invention, a method for using the mRNA of a p53 analog is provided, comprising the step of introducing the mRNA of the p53 analog into a host cell.
[0117] A lipid nanoparticle composition containing the compound of the present invention can be used according to the method described below.
[0118] Treatment methods
[0119] In another aspect, the present invention provides a method for preventing and / or treating a disease that can be prevented and / or treated by providing a p53 analog. The method comprises the step of administering a therapeutically effective amount of a polyribonucleotide encoding the aforementioned p53 analog or a pharmaceutical composition comprising a polyribonucleotide encoding the p53 analog to an individual having a disease requiring prevention or treatment.
[0120] In one embodiment, the disease requiring prevention or treatment is cancer.
[0121] In one embodiment, a pharmaceutical composition comprising a polyribonucleotide encoding the p53 analog is a composition comprising a lipid nanoparticle composition containing a polyribonucleotide encoding the p53 analog polypeptide of the present invention as described above, and optionally further comprising a pharmaceutically acceptable excipient. The amount of the lipid nanoparticle composition in the pharmaceutical composition is such that it constitutes a therapeutically effective amount. In one specific embodiment, this pharmaceutical composition is a composition for the treatment or prevention of cancer. In a more specific embodiment, the cancer is a cancer having a p53 mutation that reduces the activity of p53 in its cancer cells. Types of mutations that reduce activity include p53 point mutations, insertions, deletions, translocations, as well as p53 null mutations. Most specifically, this pharmaceutical composition is a composition for the treatment or prevention of ovarian cancer, liver cancer, gastric cancer, or lung cancer.
[0122] In this specification, unless specifically stated otherwise, the term “therapeutic effective dose” of any compound refers to an amount of the compound sufficient to delay or minimize one or more symptoms associated with any disease, condition, or state, or an amount of the compound sufficient to provide a therapeutic effect against any disease, condition, or state. The term “therapeutic effective dose” encompasses an amount that improves overall treatment, an amount that alleviates or avoids the cause of symptoms or the disease or state, and even an amount that enhances the therapeutic efficacy of other therapeutic agents.
[0123] The amount of a polyribonucleotide encoding a p53 analog or a pharmaceutical composition containing a polyribonucleotide encoding a p53 analog to be administered may vary depending on the subject being treated, the subject's age, health, sex, and weight, the type of concurrent treatment (if any), the severity of pain, the nature of the desired effect, the mode and frequency of treatment, and the judgment of the prescribing physician. The frequency of administration may also vary depending on the pharmacodynamic effect on arterial oxygen pressure. However, the most desirable dosage may be tailored to the subject as understood and determined by a person skilled in the art without excessive experimentation. This generally involves adjustments to the standard dose (e.g., a reduction in dose if the subject's body weight is low).
[0124] Although demand may vary depending on the individual case, determining the optimal range of the therapeutically effective amount of a compound, such as a polyribonucleotide encoding a p53 analog or a pharmaceutical composition thereof, is common sense in the art. When administered to humans for the curative or prophylactic treatment of conditions and disorders using a pharmaceutical composition comprising a polyribonucleotide encoding a p53 analog of the present invention, for example, a typical dose is about 0.05 mg / kg / day to about 50 mg / kg / day. These doses may be administered as a single dose or divided into multiple doses.
[0125] In another aspect of the present invention, a use of a polyribonucleotide encoding a p53 analog of the present invention or a pharmaceutical composition thereof is provided for use as a medicinal agent. In one embodiment, a use of a polyribonucleotide encoding a p53 analog of the present invention or a pharmaceutical composition thereof is provided for use in the treatment or prevention of cancer. In the most specific embodiment, the cancer is ovarian cancer, liver cancer, gastric cancer, or lung cancer.
[0126] In yet another aspect of the present invention, a use is provided for using a polyribonucleotide encoding a p53 analog of the present invention or a pharmaceutical composition thereof for the manufacture of a drug. In one embodiment, a use is provided for using a polyribonucleotide encoding a p53 analog of the present invention or a pharmaceutical composition thereof for the manufacture of a drug for the treatment or prevention of cancer. In the most specific embodiment, the cancer is ovarian cancer, liver cancer, gastric cancer, or lung cancer.
[0127] The present invention will be explained in more detail below through the following examples and experimental examples. However, these examples and experimental examples are intended only to aid in understanding the present invention and do not limit the scope of the present invention in any way. Various changes and modifications may be made to these examples, and such changes and modifications are also included within the scope of the appended claims.
[0128] [Preparation Example 1] p53 Analog and design of the gene encoding it
[0129] In the present manufacturing example, an analog of p53 and the gene encoding it were designed with the goal of improving anticancer efficacy and stability. The p53 analog can be used to inhibit the growth and progression of various cancer types.
[0130] Table 1 shows combinations of mutations introduced into the human natural p53 protein and p53 analogs. Bold text indicates the mutation locations. The human natural p53 protein contains 393 amino acids (identical to the sequence of SEQ ID NO. 1. NCBI access number NP_000537.3). The p53 analogs were designed by introducing mutations into the first transactivation domain and the second transactivation domain (TAD) corresponding to residues 14–47 based on the natural p53 sequence, the DNA binding domain (DBD) corresponding to residues 174–184 based on the natural p53 sequence, and the tetramerization domain (TET) corresponding to residues 324–356 based on the natural p53 sequence. Thus, 12 p53 analogs were selected, which are referred to hereinafter as Analog 1 through Analog 12. The amino acid sequences of the natural form p53 and analogs 1 to 12 are summarized in Table 1, focusing on the region where mutations occurred. In Table 1, bold text indicates mutations in the residues that changed in the sequence of the natural form p53.
[0131] p53 Protein Type Amino Acid Sequence Variations and Locations TAD (14–47) DBD (174–184) TET (324–356) Natural Form (WT) LSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPRRCPHHERCSDDGEYFTLQIRGRERFEMFRELNEALELKDAQAG Analog 1 LSQETFSDLWKLLPENNVLSPLPSQAMDDLMLEPRRCPHHERCSDDGEYFTLQIRGRERFEMFRELNEALELKDAQAG Analog 2 LEQETFEDLWKLLPENNVLSPLPSQAMDDLMLEPRRCPHHERCSDDGEYFTLQIRGRERFEMFRELNEALELKDAQAG Analog 3 LSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPRRCPHHERCSDDEEYFTLQIRGRERFEMREINEALELKDAMAG Analog 4LSQGTFSYLGKLLPEKLVLSPLPSQAMDDLMLSPRRCPHHERCSDDGEYFTLQIRGRERFEMFRELNEALELKDAQAGAnalog 5LSQGTFSYLGKLLPEKLVLSPLPSQAMDDLMLSPRRCPHHERCSDDEEYFTLQIRGRERFEMLREINEALELKDAMAGAnalog 6LDSQEFAELWEKNLPENNVLSPLPSQAMDDLMLSRRCPHHERCSDDGEYFTLQIRGRERFEMFRELNEALELKDAQAGAnalog 7LDSQEFAELWEKNLPENNVLSPLPSQAMDDLMLSRRCPHHERCSDDEEYFTLQIRGRERFEMLREINEALELKDAMAGAnalog 8LSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPRRCPHHRECSDDGEYFTLQIRGRERFEMFRELNEALELKDAQAGAnalog 9LSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPRRCPHHKDCSDDGEYFTLQIRGRERFEMFRELNEALELKDAQAGAnalog 10LSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPRRCPHHKDCSDDEEYFTLQIRGRERFEMLREINEALELKDAMAGAnalog11LSQGTFSYLGKLLPEKLVLSPLPSQAMDDLMLSPRRCPHHKDCSDDGEYFTLQIRGRERFEMFRELNEALELKDAQAGAnalog 12LSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPRRCPHHRECSDDEEYFTLQIRGRERFEMLREINEALELKDAMAG
[0132] Table 2 below shows the natural p53 protein of sequence number 1 (sequence of NCBI access number NP_000537.3) and the full-length sequences of 12 p53 analogs (sequence numbers 2 to 13).
[0133] p53 단백질 종류아미노산 서열천연형(서열번호 1)MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 1(서열번호 2)MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLEPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 2(서열번호3)MEEPQSDPSVEPPLEQETFEDLWKLLPENNVLSPLPSQAMDDLMLEPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 3(서열번호 4)MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDEEYFTLQIRGRERFEMLREINEALELKDAMAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 4(서열번호5)MEEPQSDPSVEPPLSQGTFSYLGKLLPEKLVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 5(서열번호 6)MEEPQSDPSVEPPLSQGTFSYLGKLLPEKLVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDEEYFTLQIRGRERFEMLREINEALELKDAMAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 6(서열번호7)MEEPQSDPSVEPPLDSQEFAELWEKNLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 7(서열번호 8)MEEPQSDPSVEPPLDSQEFAELWEKNLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDEEYFTLQIRGRERFEMLREINEALELKDAMAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 8(서열번호9)MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHRECSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 9(서열번호 10)MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHKDCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 10(서열번호11)MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHKDCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDEEYFTLQIRGRERFEMLREINEALELKDAMAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 11(서열번호 12)MEEPQSDPSVEPPLSQGTFSYLGKLLPEKLVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHKDCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD아날로그 12(서열번호13)MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHRECSDSDGLAPPQHLI RVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDEEYFTLQIRGRERFEMLREINEALELKDAMAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
[0134]
[0135] Table 3 below shows the DNA nucleotide sequence encoding the natural p53 protein (Sequence No. 14) and the full-length DNA nucleotide sequences encoding the 12 p53 analogs mentioned above (Sequence Nos. 15 to 26). In Table 3, the DNA nucleotide sequence of each p53 analog is a codon-optimized sequence that can efficiently produce mRNA in in vitro transcription compared to the nucleotide sequence of the human natural p53 gene (NP_000537.3).
[0136] p53 DNA Sequence Types DNA Nucleotide Sequence (5'→ 3') Natural Form (Sequence No. 14) TCCGCGAATTGAACGAGGCCCTGGAGTTGAAGGACGCTCAAGCCGGGAAGGAACCAGGTGGGTCTAGGGCCCACTCAAGCCATCTGAAGAGTAAGAAGGGCCAGTCCACTTCCAGGCACAAGAAGTTAATGTTCAAGACGGAGGGTCCTGACTCTGACTGATGA Analog 1 (Sequence No. 15) TCCGCGAATTGAACGAGGCCCTGGAGTTGAAGGACGCTCAAGCCGGGAAGGAACCAGGTGGGTCTAGGGCCCACTCAAGCCATCTGAAGAGTAAGAAGGGCCAGTCCACTTCCAGGCACAAGAAGTTAATGTTCAAGACGGAGGGTCCTGACTCTGACTGATGA Analog 2 (Sequence No. 16)TCCGCGAATTGAACGAGGCCCTGGAGTTGAAGGACGCTCAAGCCGGGAAGGAACCAGGTGGGTCTAGGGCCCACTCAAGCCATCTGAAGAGTAAGAAGGGCCAGTCCACTTCCAGGCACAAGAAGTTAATGTTCAAGACGGAGGGTCCTGACTCTGACTGATGAAnalog 3 (SEQ ID NO: 17)TCCGCGAGATCAACGAGGCCCTTGAACTCAAGGATGCTATGGCTGGGAAGGAGCCAGGAGGAAGCAGAGCACATTCAAGCCACCTGAAATCCAAGAAGGGACAATCGACTTCGCGGCACAAAAAACTGATGTTCAAAACGGAAGGTCCTGACAGCGACTGATGAAnalog 4 (SEQ ID NO: 18) TCCGGGAACTAAACGAAGCCCTGGAGCTTAAGGATGCGCAGGCTGGTAAGGAACCCGGCGGTAGCAGAGCCCACTCTAGCCACTTAAAATCCAAGAAGGGTCAGTCTACAAGTCGTCACAAAAAACTGATGTTTAAGACAGAAGGGCCCGACTCCGATTGATGAAnalog 5 (SEQ ID NO:19)TCCGCGAGATCAACGAGGCCCTTGAACTCAAGGATGCCATGGCCGGGAAGGAGCCTGGAGGCAGTCGTGCGCACTCATCTCACCTGAAGAGTAAGAAGGGCCAGTCCACTAGCAGACATAAGAAATTAATGTTTAAGACAGAGGGTCCAGACTCCGACTGATGA아날로그 6(서열번호 20)TGTTTAGGGAGCTCAACGAGGCTCTGGAGCTGAAGGACGCCCAGGCCGGGAAGGAGCCAGGGGGAAGCCGGGCGCACAGCTCTCACCTCAAGAGCAAGAAGGGGCAGAGTACGAGTCGGCACAAAAAACTGATGTTCAAGACAGAGGGCCCGGATTCTGACTGATGA아날로그 7(서열번호 21)TGCTGCGGGAAATCAATGAGGCTTTGGAGCTCAAGGATGCAATGGCCGGCAAGGAACCAGGAGGGTCCAGAGCCCACTCTTCTCACCTGAAATCCAAGAAGGGCCAGAGCACAAGTCGACATAAGAAACTCATGTTCAAAACCGAGGGTCCCGACAGCGACTGATGA아날로그 8(서열번호 22)TCCGCGAATTGAACGAGGCCCTGGAGTTGAAGGACGCTCAAGCCGGGAAGGAACCAGGTGGGTCTAGGGCCCACTCAAGCCATCTGAAGAGTAAGAAGGGCCAGTCCACTTCCAGGCACAAGAAGTTAATGTTCAAGACGGAGGGTCCTGACTCTGACTGATGA아날로그 9(서열번호 23)TCCGCGAATTGAACGAGGCCCTGGAGTTGAAGGACGCTCAAGCCGGGAAGGAACCAGGTGGGTCTAGGGCCCACTCAAGCCATCTGAAGAGTAAGAAGGGCCAGTCCACTTCCAGGCACAAGAAGTTAATGTTCAAGACGGAGGGTCCTGACTCTGACTGATGA아날로그 10(서열번호24)TCCGCGAGATCAACGAGGCCCTTGAACTCAAGGATGCTATGGCTGGGAAGGAGCCAGGAGGAAGCAGAGCACATTCAAGCCACCTGAAATCCAAGAAGGGACAATCGACTTCGCGGCACAAAAAACTGATGTTCAAAACGGAAGGTCCTGACAGCGACTGATGAAnalog 11 (SEQ ID NO: 25) TCCGGGAACTAAACGAAGCCCTGGAGCTTAAGGATGCGCAGGCTGGTAAGGAACCCGGCGGTAGCAGAGCCCACTCTAGCCACTTAAAATCCAAGAAGGGTCAGTCTACAAGTCGTCACAAAAAACTGATGTTTAAGACAGAAGGGCCCGACTCCGATTGATGAAnalog 12 (SEQ ID NO: 26)TCCGCGAGATCAACGAGGCCCTTGAACTCAAGGATGCTATGGCTGGGAAGGAGCCAGGAGGAAGCAGAGCACATTCAAGCCACCTGAAATCCAAGAAGGGACAATCGACTTCGCGGCACAAAAAACTGATGTTCAAAACGGAAGGTCCTGACAGCGACTGATGA
[0137] [Preparation Example 2] Design of p53 mRNA construct and preparation of vector for its preparation
[0138] In this example, a template vector was prepared for transcribing in vitro mRNA expressing human natural p53 or p53 analogs of SEQ ID NOs 1 to 13 obtained in Preparation Example 1.
[0139] The above template vector was specifically constructed as follows. First, pUC57-Amp R pUC57-Kan, in which the antibiotic resistance gene was replaced with the kanamycin resistance gene from the vector (NovoPro, #012363) R A vector was constructed. Next, DNA encoding each p53 protein gene listed in Table 4, namely the T7 promoter-5' UTR-ORF-3' UTR-polyadenine tail, was synthesized. The above pUC57-Kan RAfter cleaving the vector and each p53 protein gene by treating with restriction enzymes HindIII and XhoI, the two cleaved sequences were ligated using a ligase to produce pUC57-Kan for each p53 protein expression R -p53 vector obtained.
[0140] In addition to the above genes, the vector includes the E. coli replication origin (ColEq ori) and a selection marker gene. In Table 4, the T7 promoter refers to the region involved in the initiation of mRNA transcription. Additionally, the nucleotide underlined in the T7 promoter is the HindIII restriction enzyme recognition sequence.
[0141] The above template vector contains DNA encoding the T7 promoter-5' UTR-ORF-3' UTR-polyadenine tail. The above p53 protein mRNA construct contains the 5' UTR-ORF-3' UTR-polyadenine tail.
[0142] Figure 1 shows each pUC57-Kan for p53 protein expression R -p53 This is a diagram schematically representing the vector.
[0143] Table 4 below is pUC57-Kan R This shows the promoter (SEQ No. 27), the polynucleotide encoding the 5' UTR (SEQ No. 28), the polynucleotides encoding the natural or analog p53 (SEQ Nos. 14 to 26), the polynucleotide encoding the 3' UTR (SEQ No. 29), and the polyadenine tail sequence (SEQ No. 30) included in the -p53 vector. In Table 4, the nucleotides underlined in SEQ No. 27 are the HindIII restriction enzyme recognition sequences. In Table 4, the nucleotides underlined in SEQ No. 29 are the XhoI restriction enzyme recognition sequences, and the nucleotides in bold are the NheI restriction enzyme recognition sequences. Additionally, the nucleotides underlined in SEQ No. 30 in Table 4 are the EcoRI restriction enzyme recognition sequences.
[0144]
[0145] Table 5 below shows the ribonucleotide sequences of natural p53 mRNA transcribed from this template vector DNA (Sequence No. 31) or the ribonucleotide sequences of p53 analog mRNA (Sequence Nos. 32 to 43).
[0146] p53 type mRNA sequence (5'→3') Natural form (WT) (Sequence No. 31) Analog1CCGAAGAAGAAACCCCUCGACGGAGAGUACUUUACUCUACAAAUUAGGGGGAGAGAAAGAUUUGAGAUGUUCCGCGAAUUGAACGAGGCCCUGGAGUUGAAGGACGCUCAAGCCGGGAAGGAACCAGGUGGGUCUAGGGCCCACUCAAGCCAUCUGAAGAGUAAGAAGGGCCAGUCCACUUCCAGGCACAAGAAGUUAAUGUUCAAGACGGAGGGUCCUGACUCUGACUGAUGACUCGAGCAUACCAUAAAACCAAACAUAUACCCGAGGUCCUUCGGCAUUGGGAGGAUGAUACGCAAGAAGCAUGAUUCCCCACCAGACCGAAUGCAGGUUUAAGUGAGGGGUGCAAACUUGUGUCACUAACCAUUAUUAUGAAGAAAAAAACAGCCAAAAAAAGAGCCACAAGGCGGCGCGGUAUGCUAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAGCGAAUU(서열번호 32)아날로그2CCGAAGAAGAAACCCCUCGACGGAGAGUACUUUACUCUACAAAUUAGGGGGAGAGAAAGAUUUGAGAUGUUCCGCGAAUUGAACGAGGCCCUGGAGUUGAAGGACGCUCAAGCCGGGAAGGAACCAGGUGGGUCUAGGGCCCACUCAAGCCAUCUGAAGAGUAAGAAGGGCCAGUCCACUUCCAGGCACAAGAAGUUAAUGUUCAAGACGGAGGGUCCUGACUCUGACUGAUGACUCGAGCAUACCAUAAAACCAAACAUAUACCCGAGGUCCUUCGGCAUUGGGAGGAUGAUACGCAAGAAGCAUGAUUCCCCACCAGACCGAAUGCAGGUUUAAGUGAGGGGUGCAAACUUGUGUCACUAACCAUUAUUAUGAAGAAAAAAACAGCCAAAAAAAGAGCCACAAGGCGGCGCGGUAUGCUAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAGCGAAUU(서열번호 33)아날로그3CCCAAGAAGAAGCCUCUCGAUGAGGAGUACUUCACCUUACAGAUACGCGGAAGAGAGAGAUUCGAGAUGCUCCGCGAGAUCAACGAGGCCCUUGAACUCAAGGAUGCUAUGGCUGGGAAGGAGCCAGGAGGAAGCAGAGCACAUUCAAGCCACCUGAAAUCCAAGAAGGGACAAUCGACUUCGCGGCACAAAAAACUGAUGUUCAAAACGGAAGGUCCUGACAGCGACUGAUGACUCGAGCAUACCAUAAAACCAAACAUAUACCCGAGGUCCUUCGGCAUUGGGAGGAUGAUACGCAAGAAGCAUGAUUCCCCACCAGACCGAAUGCAGGUUUAAGUGAGGGGUGCAAACUUGUGUCACUAACCAUUAUUAUGAAGAAAAAAACAGCCAAAAAAAGAGCCACAAGGCGGCGCGGUAUGCUAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAGCGAAUU(서열번호 34)아날로그4CCCAAGAAGAAGCCAUUGGACGGAGAAUACUUCACCCUGCAGAUUAGGGGACGCGAGAGAUUCGAGAUGUUCCGGGAACUAAACGAAGCCCUGGAGCUUAAGGAUGCGCAGGCUGGUAAGGAACCCGGCGGUAGCAGAGCCCACUCUAGCCACUUAAAAUCCAAGAAGGGUCAGUCUACAAGUCGUCACAAAAAACUGAUGUUUAAGACAGAAGGGCCCGACUCCGAUUGAUGACUCGAGCAUACCAUAAAACCAAACAUAUACCCGAGGUCCUUCGGCAUUGGGAGGAUGAUACGCAAGAAGCAUGAUUCCCCACCAGACCGAAUGCAGGUUUAAGUGAGGGGUGCAAACUUGUGUCACUAACCAUUAUUAUGAAGAAAAAAACAGCCAAAAAAAGAGCCACAAGGCGGCGCGGUAUGCUAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAGCGAAUU(서열번호 35)아날로그5CCAAAAAAAAAACCCCUGGAUGAGGAGUACUUUACCCUGCAGAUUCGGGGCCGGGAGCGCUUUGAGAUGCUCCGCGAGAUCAACGAGGCCCUUGAACUCAAGGAUGCCAUGGCCGGGAAGGAGCCUGGAGGCAGUCGUGCGCACUCAUCUCACCUGAAGAGUAAGAAGGGCCAGUCCACUAGCAGACAUAAGAAAUUAAUGUUUAAGACAGAGGGUCCAGACUCCGACUGAUGACUCGAGCAUACCAUAAAACCAAACAUAUACCCGAGGUCCUUCGGCAUUGGGAGGAUGAUACGCAAGAAGCAUGAUUCCCCACCAGACCGAAUGCAGGUUUAAGUGAGGGGUGCAAACUUGUGUCACUAACCAUUAUUAUGAAGAAAAAAACAGCCAAAAAAAGAGCCACAAGGCGGCGCGGUAUGCUAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAGCGAAUU(서열번호 36)아날로그6CAACCUAAGAAAAAACCUCUGGACGGUGAGUACUUCACCCUGCAGAUAAGAGGGAGGGAGCGCUUCGAGAUGUUUAGGGAGCUCAACGAGGCUCUGGAGCUGAAGGACGCCCAGGCCGGGAAGGAGCCAGGGGGAAGCCGGGCGCACAGCUCUCACCUCAAGAGCAAGAAGGGGCAGAGUACGAGUCGGCACAAAAAACUGAUGUUCAAGACAGAGGGCCCGGAUUCUGACUGAUGACUCGAGCAUACCAUAAAACCAAACAUAUACCCGAGGUCCUUCGGCAUUGGGAGGAUGAUACGCAAGAAGCAUGAUUCCCCACCAGACCGAAUGCAGGUUUAAGUGAGGGGUGCAAACUUGUGUCACUAACCAUUAUUAUGAAGAAAAAAACAGCCAAAAAAAGAGCCACAAGGCGGCGCGGUAUGCUAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAGCGAAUU(서열번호 37)아날로그7CAGCCCAAGAAGAAGCCUCUGGAUGAAGAAUACUUUACACUUCAAAUCCGCGGAAGAGAGAGGUUUGAAAUGCUGCGGGAAAUCAAUGAGGCUUUGGAGCUCAAGGAUGCAAUGGCCGGCAAGGAACCAGGAGGGUCCAGAGCCCACUCUUCUCACCUGAAAUCCAAGAAGGGCCAGAGCACAAGUCGACAUAAGAAACUCAUGUUCAAAACCGAGGGUCCCGACAGCGACUGAUGACUCGAGCAUACCAUAAAACCAAACAUAUACCCGAGGUCCUUCGGCAUUGGGAGGAUGAUACGCAAGAAGCAUGAUUCCCCACCAGACCGAAUGCAGGUUUAAGUGAGGGGUGCAAACUUGUGUCACUAACCAUUAUUAUGAAGAAAAAAACAGCCAAAAAAAGAGCCACAAGGCGGCGCGGUAUGCUAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAGCGAAUU(서열번호 38)아날로그8CCGAAGAAGAAACCCCUCGACGGAGAGUACUUUACUCUACAAAUUAGGGGGAGAGAAAGAUUUGAGAUGUUCCGCGAAUUGAACGAGGCCCUGGAGUUGAAGGACGCUCAAGCCGGGAAGGAACCAGGUGGGUCUAGGGCCCACUCAAGCCAUCUGAAGAGUAAGAAGGGCCAGUCCACUUCCAGGCACAAGAAGUUAAUGUUCAAGACGGAGGGUCCUGACUCUGACUGAUGACUCGAGCAUACCAUAAAACCAAACAUAUACCCGAGGUCCUUCGGCAUUGGGAGGAUGAUACGCAAGAAGCAUGAUUCCCCACCAGACCGAAUGCAGGUUUAAGUGAGGGGUGCAAACUUGUGUCACUAACCAUUAUUAUGAAGAAAAAAACAGCCAAAAAAAGAGCCACAAGGCGGCGCGGUAUGCUAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAGCGAAUU(서열번호 39)아날로그9CCGAAGAAGAAACCCCUCGACGGAGAGUACUUUACUCUACAAAUUAGGGGGAGAGAAAGAUUUGAGAUGUUCCGCGAAUUGAACGAGGCCCUGGAGUUGAAGGACGCUCAAGCCGGGAAGGAACCAGGUGGGUCUAGGGCCCACUCAAGCCAUCUGAAGAGUAAGAAGGGCCAGUCCACUUCCAGGCACAAGAAGUUAAUGUUCAAGACGGAGGGUCCUGACUCUGACUGAUGACUCGAGCAUACCAUAAAACCAAACAUAUACCCGAGGUCCUUCGGCAUUGGGAGGAUGAUACGCAAGAAGCAUGAUUCCCCACCAGACCGAAUGCAGGUUUAAGUGAGGGGUGCAAACUUGUGUCACUAACCAUUAUUAUGAAGAAAAAAACAGCCAAAAAAAGAGCCACAAGGCGGCGCGGUAUGCUAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAGCGAAUU(서열번호 40)아날로그10CCCAAGAAGAAGCCUCUCGAUGAGGAGUACUUCACCUUACAGAUACGCGGAAGAGAGAGAUUCGAGAUGCUCCGCGAGAUCAACGAGGCCCUUGAACUCAAGGAUGCUAUGGCUGGGAAGGAGCCAGGAGGAAGCAGAGCACAUUCAAGCCACCUGAAAUCCAAGAAGGGACAAUCGACUUCGCGGCACAAAAAACUGAUGUUCAAAACGGAAGGUCCUGACAGCGACUGAUGACUCGAGCAUACCAUAAAACCAAACAUAUACCCGAGGUCCUUCGGCAUUGGGAGGAUGAUACGCAAGAAGCAUGAUUCCCCACCAGACCGAAUGCAGGUUUAAGUGAGGGGUGCAAACUUGUGUCACUAACCAUUAUUAUGAAGAAAAAAACAGCCAAAAAAAGAGCCACAAGGCGGCGCGGUAUGCUAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAGCGAAUU(서열번호 41)아날로그11CCCAAGAAGAAGCCAUUGGACGGAGAAUACUUCACCCUGCAGAUUAGGGGACGCGAGAGAUUCGAGAUGUUCCGGGAACUAAACGAAGCCCUGGAGCUUAAGGAUGCGCAGGCUGGUAAGGAACCCGGCGGUAGCAGAGCCCACUCUAGCCACUUAAAAUCCAAGAAGGGUCAGUCUACAAGUCGUCACAAAAAACUGAUGUUUAAGACAGAAGGGCCCGACUCCGAUUGAUGACUCGAGCAUACCAUAAAACCAAACAUAUACCCGAGGUCCUUCGGCAUUGGGAGGAUGAUACGCAAGAAGCAUGAUUCCCCACCAGACCGAAUGCAGGUUUAAGUGAGGGGUGCAAACUUGUGUCACUAACCAUUAUUAUGAAGAAAAAAACAGCCAAAAAAAGAGCCACAAGGCGGCGCGGUAUGCUAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAGAGCGAAUU(서열번호 42)아날로그(Sequence No. 43)
[0147] Table 6 below describes exemplary 5' UTR sequences that can be used in the present invention. This 5' untranslated region is a non-natural sequence that does not exist in nature; it was selected as a random sequence with a length of 50 bp or 70 bp and a mean free energy of 0 that does not form secondary structures between bases. In addition, to optimize capping for protecting the 5' end of the mRNA, the 5' end of the 5' untranslated region was designed to start with 'AG' and end with 'GCCACC', a Kozak sequence for stable gene expression.
[0148]
[0149] Table 7 below describes exemplary non-natural 3' untranslated region sequences that can be used in the present invention. A random sequence combination of the same length as the 3' UTR of human complement component 3 (C3) or the 3' UTR of human cytochrome P450 2E1, which is known to have excellent activity for increasing gene yield, was constructed, and sequences whose secondary structure was similar to the 3' UTR of C3 or the 3' UTR of cytochrome P450 2E1 were selected. Then, a process was performed to remove potential AU-rich element sequences that could cause mRNA instability from the selected mRNA sequences, thereby selecting eight final non-natural 3' UTR sequences.
[0150]
[0151] [Preparation Example 3] Production and yield of gene product
[0152] Transformed E. coli were obtained by introducing a vector containing the structure of the sequence encoding the 5' UTR-p53 analog protein prepared in Preparation Example 2—specifically the 3' UTR—polyadenine tail. The obtained E. coli were cultured to proliferate E. coli containing plasmid DNA that serves as the mRNA template. The proliferated E. coli were separated from the culture medium by high-speed centrifugation, and cell-derived template DNA was obtained using a previously known alkaline extraction method. The obtained template DNA was linearized using a restriction enzyme recognition sequence located at the end of the polyadenine tail. mRNA having the nucleotide sequence of the sequence encoding the 5' UTR-p53 analog protein—specifically the 3' UTR—polyadenine tail was produced by in vitro transcription using the linearized cell-derived template DNA. The 5' UTR sequence and 3' UTR sequence of the mRNA obtained in this way are the sequences of SEQ ID NO. 49 and SEQ ID NO. 54, respectively, and the polyadenine tail is the same as the aforementioned sequence.
[0153] Specifically, linearized plasmid DNA 10 ng / μL, Hanmi Cap reagent 4 mM, NTP 5 mM, N 1 5 U / μL of T7 RNA polymerase was added to an aqueous solution containing 5 mM methylpseudouridine, 20 mM magnesium ion salt, 10 mM DTT, 0.01 U / μL of inorganic pyrophosphatase (PPase), and 1 U / μL of RNA degradation inhibitor, and the resulting reaction mixture was incubated at 37°C for at least one hour to allow the in vitro transcription reaction to proceed. Hanmi cap reagent is a reagent for co-transcriptional capping of mRNA, and m 7 A G(3'-mesyloxy)pppA(2'-OMe)pG cap structure, that is, a cap analog of Example 8 described in Korean Patent Publication No. 10-2023-0141482 disclosed on October 10, 2023, is formed. The reaction mixture was treated with a DNA degrading enzyme, and the RNA was purified using the Monarch® RNA Cleanup Kit (New England Biolabs). As a result, in the ribonucleotide sequences of SEQ ID NOs. 31 to 43, uridine N 1 mRNA with sequences replaced with methylpseudouridine was produced. The 5'-UTR, p53 analog protein sequence, nucleotide sequence composition of the 3'-UTR included in these mRNAs, and the synthesis yield according to the UTR combination are shown in Table 8 below.
[0154]
[0155] [Example 1]
[0156] Confirmation of cell growth inhibitory ability in cancer cells with p53 mutations
[0157] In this example, the effect of the p53 mRNA prepared in Example 3 on cancer cells having a p53 mutation was confirmed. ES-2 (ATCC, #CRL-1978) and H1373 (Korea Cell Line Bank, #KCLB91373.1G) cell lines were used for cancer cells having a p53 mutation.
[0158] ES-2 is an ovarian cancer cell line with a p53 S241F mutation. ES-2 is a cancer cell line with fibroblast-like morphology isolated from the ovaries of Black women with clear cell carcinoma. H1373, also known as NCI-H1373, is a lung cancer cell line with a p53 P47L mutation. H1373 is an epithelial-like cell isolated from a Black cancer patient.
[0159] Specifically, through in vitro experiments as follows, uridine N from the nucleotide sequences of p53 analogs 3 and 4 obtained in Preparation Example 3 1 - Modified mRNA replaced with methylpseudouridine was delivered to each cancer cell line, and cell growth inhibitory activity was confirmed. ES-2 and H1373 cells were placed in 96-well plates at a rate of 5 × 10⁶ per well, respectively. 3 Cells / 200 μL, 3 x 10⁶ 3 mRNA and Lipofectamine 24 hours after seeding at a ratio of cells / 200 μL TM MessengerMAX TM Transfection reagent was mixed to a concentration of 0.2 μL per well. The p53 analog mRNA to be administered to ES-2 and H1373 cells was treated in 8 steps of dilution, starting from 0.25 μg / mL and 1 μg / mL, respectively, and decreasing the concentration by half.
[0160] Cell viability was measured using the WST-8 cell viability assay kit (BIOMAX, Cat No. QM5000). Day 0 was set as the day for adding p53 analog mRNA to the cells. Cells seeded separately the previous day were mixed with the WST-8 reagent in a 1:10 ratio into the culture medium and incubated for 2 hours, after which the absorbance at 450 nm was measured. Plates treated with p53 analog mRNA were cultured at 37°C for 3 or 5 days. After the culture was completed, the WST-8 reagent was mixed with the cell medium in a 1:10 ratio and incubated for 2 hours; the absorbance at 450 nm was measured, and a Graphpad Prism was used. TM Using software, Half maximal growth inhibition concentration (GI) 50 ) values were derived. By correcting using the 0-day and blank absorbance values as baselines, the relative cell growth rate compared to a negative control not treated with p53 analog mRNA was derived.
[0161] Figures 2a and 2b show the results of confirming the growth inhibitory ability of each cell by the produced p53 mRNA. As shown in Figures 2a and 2b, it was confirmed that p53 mRNA inhibits the growth of ovarian cancer and lung cancer cell lines with defects in the p53 gene, and the superior cancer cell growth inhibitory ability of p53 analog mRNA compared to natural p53 mRNA was confirmed.
[0162] In Table 9 below, the cancer cell growth inhibitory activity of p53 analog mRNA in ES-2 cell lines is summarized as relative activity to natural p53 mRNA.
[0163]
[0164] [Example 2]
[0165] Evaluation of the anticancer efficacy of p53 analog mRNA in an ovarian cancer xenograft model
[0166] To evaluate the anticancer efficacy of the p53 mRNA analog according to the present invention, the antitumor efficacy was assessed by administering the p53 analog mRNA to an ovarian cancer mouse model xenografted with ES-2 cells and observing changes in tumor volume. In the experimental group, uridine from the nucleotide sequences of nucleotides 3 and 12 of the natural p53 mRNA or p53 analog N 1 Lipid nanoparticles containing modified mRNA replaced with methyl-pseudouridine were administered intravenously at a dose of 30 μg per animal (in a 100 μL solution of phosphate-buffered saline (PBS)) based on mRNA content, twice a week for three weeks. In the negative control group, Dulbecco's phosphate-buffered saline (D-PBS) solution containing lipid nanoparticles without mRNA was administered at the same volume. Specifically, ES-2 cells (ATCC) cultured in cell culture flasks were subcutaneously injected into the dorsal side of 5-week-old BALB / c nude mice, and tumor volume was monitored a few days later once a tumor was observed visually. Five mice were assigned to each group to ensure similar tumor volumes at the start of administration. During the experiment, mouse body weight and tumor volume were measured twice a week. Tumor volume was measured using a digital caliper, and the longest and shortest axes were measured and calculated using the following formula.
[0167] Tumor size (mm) 3 ): ½ × Width (mm) × Shortest axis (mm) × Longest axis (mm)
[0168] Tumor volumes of each group were observed up to day 21 from the start of administration. As a result, the anticancer efficacy of p53 mRNA analogs 3 and 12 showed significant tumor growth inhibition compared to the negative control group in the ES-2 xenograft model, as well as higher efficacy than the natural form (Fig. 3a). Additionally, no decrease in mouse body weight was observed due to continuous mRNA administration for 3 weeks, indicating stability in terms of side effects (Fig. 3b). On day 21 after administration, tumor growth inhibition was confirmed to be 48.7%, 62.0%, and 52.7% in the natural form, analog 3, and analog 12 mRNA administration groups, respectively (Fig. 3c).
[0169] [Example 3]
[0170] Confirmation of tetramer (tetramer) formation of p53 analog in H1299 cells
[0171] Lipofectamine on mRNA prepared in the example TM MessengerMAX TM Transfection Reagent (Thermo Scientific TM mRNA was delivered to H1299 cells using LMRNA (Cat No. LMRNA001), and it was confirmed whether the expressed p53 protein forms a tetramer. To this end, in vitro experiments were conducted as follows. Cells were placed in a 6-well plate at a rate of 3 × 10⁶ per well. 5 24 hours after seeding cells / 2 mL, uridine from the nucleotide sequence of p53 analog 3 N 1 - Modified mRNA replaced with methylpseudouridine and Lipofectamine TM MessengerMAX TMTransfection reagent was mixed at a ratio of 0.5 μL per 1 μg of mRNA and reacted for 20 minutes; subsequently, 1 μg of each reaction product was added, and the mixture was incubated for 24 hours. Incubation was performed in the medium at 37°C under a 5% CO2 environment. After the incubation was completed, lysis buffer, M-PER TM (Mammalian Protein Extraction Reagent)(Thermo Scientific TM , Cat No. 78501) Add 100 μL / well to rupture cells and extract proteins, then Pierce TM BCA Protein Assay Kit (Thermo Scientific TM BCA protein quantification was performed using (Cat No. 23225).
[0172] To crosslink the p53 subunits, glutaraldehyde (Sigma Aldrich, Cat No. G6257), diluted in PBS (Solbio, Cat No. PBS 001) to a final glutaraldehyde concentration of 0.1%, was added to the sample obtained as above and reacted at 4°C for 10 minutes. Glycine (Sigma Aldrich, Cat No. G8898) was added to a final glycine concentration of 100 mM and reacted at 20°C for 15 minutes to stop the crosslinking reaction, after which the solution was diluted with a 5× reducing dye (10% SDS, 0.5% bromophenol blue, 50% glycerol, 0.5% 2-mercaptoethanol, 250 mM tris pH 6.8) and boiled at 70°C for 10 minutes. Western blot experiments were performed on diluted samples using the anti-p53 monoclonal antibody 7F5 (CST, Cat No. #74556F) and the anti-GAPDH antibody (Santa Cruz, Cat No. 32223). Cell lysate from cells that had not endocytosed p53 was used as a negative control.
[0173] Figure 4 shows the results of Western blot analysis confirming that the expressed p53 protein forms a tetramer when the produced p53 RNA is introduced into cells. As shown in Figure 4, in the sample not reacted with glutaraldehyde, the p53 protein was identified only in monomeric form, whereas in the sample cross-linked with glutaraldehyde, it was confirmed that the formation of both dimers and tetramers of the p53 protein was maintained in both the natural form and Analog 3. Considering that the p53 protein is a transcription factor that acts in a tetrameric form to maintain high functional activation and DNA binding ability, the significantly higher tetramer formation of Analog 3 compared to the natural form suggests that it can function as a more efficient transcription factor.
[0174] [Example 4]
[0175] Confirmation of transcriptional activity of p53 protein in H1299 cell line
[0176] Using the p53 null cell line H1299, uridine N from the nucleotide sequences of natural p53 mRNA and p53 analogues 1 Transcriptional activity ability based on tetramer formation of modified mRNA replaced with methylpseudouridine was compared and evaluated.
[0177] 4 × 10 cells per well in a 6-well plate 5 Cells were seeded at a rate of 2 mL / cells and cultured for 24 hours in RPMI medium containing 10% FBS at 37°C in a 5% CO2 incubator. After 24 hours, 125 ng, 250 ng, and 500 ng of native p53 mRNA or p53 analog #3 mRNA were added to each well to treat the mRNA with Lipofectamine. TM MessengerMAX TM Transfection reagent was mixed at a ratio of 0.25 μL per 125 ng of mRNA and reacted for 20 minutes; subsequently, the reaction products were transferred to separate well plates and incubated for 24 hours. After incubation, cell nuclei were extracted using a Nuclear Extraction Kit (Abcam, Cat No. ab113474), followed by piercing TM BCA Protein Assay Kit (Thermo Scientific TM BCA protein quantification was performed using the p53 Transcription Factor Assay Kit (Abcam, Cat No. 23225). The extracted protein samples were adjusted to a uniform concentration of 50 μg / 50 μL using the Cell Lysis Buffer (CLB) included in the p53 Transcription Factor Assay Kit (Abcam, Cat No. ab207225).
[0178] According to the manufacturer's instructions, 40 μL / well of Complete Binding Buffer (CBB) was dispensed into a 96-well plate coated with a deoxyoligonucleotide containing a p53 DNA binding site (a double-stranded deoxyribonucleotide containing the p53 consensus DNA binding sequence 5'-GGACATGCCCGGGCATGTCC-3'), and 10 μg / 10 μL of each protein sample was added. The plates were then reacted at 100 rpm using a rocking shaker at room temperature for 1 hour. After 1 hour, the plates were washed three times with the wash solution enclosed in the kit, followed by the addition of 100 μL of the primary p53 antibody per well, and the plates were reacted at room temperature for 1 hour. After 1 hour, the plates were washed three times with the wash solution, and 100 μL of the secondary HRP antibody per well was added, followed by the reaction at room temperature for 1 hour. After the second antibody reaction was completed, the wells were washed three times with a washing solution, and 100 μL of developing solution was dispensed per well and allowed to develop at room temperature for 10 minutes. After 10 minutes, a stop solution was added, and the absorbance was measured at 450 nm using a spectrophotometer (Molecular devices, SpectraMax 190).
[0179] Figure 5 shows the results of confirming the degree of transcriptional activity of expressed p53 proteins after introducing natural p53 mRNA or p53 analog 3 mRNA into cells. It was confirmed that in both cases, transcriptional activity increased as the amount of mRNA introduced into the cells increased. In addition, higher transcriptional activity of analog 3 was observed compared to natural p53 at all mRNA treatment concentrations of 125 ng, 250 ng, and 500 ng. Considering that the tetramerization ability of analog 3 was superior to that of natural p53 in the previous Example 6, these results suggest that the superior tetramerization ability of analog 3 can increase transcriptional activity within the cell nucleus.
[0180] [Example 5]
[0181] Confirmation of cell growth inhibitory ability in cancer cells with p53 mutations
[0182] In this example, the effect of the p53 analog mRNA obtained in Preparation Example 3 described above on the cell growth of cancer cells having a p53 mutation was confirmed. As cancer cells having a p53 mutation, Huh7 (Korea Cell Line Bank, #60104), Hep3B (Korea Cell Line Bank, #88064), NUGC3 (JCRB, #JCRB0822), HCC827 (ATCC, #CRL-2868), and H1975 (ATCC, #CRL-5908) cell lines were used.
[0183] Huh7 is a hepatocellular carcinoma (HCC) cell line with a p53 Y220C mutation. This cell line was isolated from a liver tumor of a Japanese male and exhibits hepatocellular-derived epithelial-like morphology. Hep3B is a p53-null hepatocellular carcinoma cell line. It was isolated from hepatocellular carcinoma derived from the liver of an African American male and exhibits an epithelial-like morphology. NUGC-3 is a gastric adenocarcinoma cell line with a p53 Y220C mutation. It was isolated from a metastatic gastric cancer lesion of a Japanese male and exhibits epithelial-like, adherent morphology. HCC827 is a lung adenocarcinoma cell line with a p53 V218del mutation and a deletion in EGFR exon 19. It was derived from the lungs of a Caucasian female and exhibits an epithelial-like morphology. H1975 is a lung adenocarcinoma cell line with p53 R273H mutation and EGFR L858R and T790 mutations. It was isolated from the lungs of a non-smoking Caucasian woman and exhibits an epithelial cell morphology.
[0184] Specifically, through in vitro experiments as follows, uridine N from the nucleotide sequence of p53 analog 3 obtained in Preparation Example 3 1 - Modified mRNA replaced with methylpseudouridine was delivered to each cancer cell line, and cell growth inhibitory ability was confirmed. 8×10⁴ Huh7 cells in a 96-well plate 3 1 / 200 μL, 3×10⁶ Hep3B cells 3 Cells / 200 μL, 5×10⁶ NUGC3 cells 3 3×10⁶ HCC827 cells / 200 μL 3 3×10⁶ H1975 cells / 200 μL 3 p53 mRNA and Lipofectamine at a rate of 200 μL / dog 24 hours after seeding TM MessengerMAX TM Transfection Reagent (Thermo Scientific TM LMRNA (company catalog number LMRNA001) was mixed with p53 analog mRNA to a concentration of 0.2 μL per well. The p53 analog mRNA administered to each cell was treated in 8 steps of dilution, starting from 4 μg / mL and decreasing the concentration by half.
[0185] Cell viability was measured using the WST-8 cell viability assay kit (BIOMAX catalog number QM5000). Day 0 was set as the day for inoculating the cells with p53 analog mRNA. Cells inoculated separately the previous day were mixed with the WST-8 reagent in a 1:10 ratio into the culture medium and incubated for 2 hours, after which the absorbance at 450 nm was measured. Plates treated with p53 analog mRNA were cultured at 37°C for 3 or 5 days. After the culture was completed, the WST-8 reagent was mixed with the cell medium in a 1:10 ratio and incubated for 2 hours; the absorbance at 450 nm was measured, and a Graphpad Prism was used. TMUsing software, Half maximal growth inhibition concentration (GI) 50 ) values were derived. By correcting using the 0-day and blank absorbance values as baselines, the relative cell growth rate compared to a negative control not treated with p53 analog mRNA was derived.
[0186] From the results of this experiment, the efficacy of the p53 analog mRNA of the present invention in inhibiting the growth of the aforementioned p53 mutant cancer cell line is shown in FIGS. 6a to 6e. As shown in FIGS. 6a to 6e, it was confirmed that the p53 analog mRNA of the present invention has an effect of inhibiting the growth of liver cancer, gastric cancer, and lung cancer cell lines having a defect in the p53 gene.
[0187] Although the present invention has been described with reference to limited embodiments as above, the technical concept and scope of the present invention are not limited to these aforementioned embodiments. In addition to the invention of the patent claims described below, various modifications or variations of the invention described in the patent claims that are obvious to those skilled in the art to which this invention belongs are also included within the scope of the present invention within the equivalent scope of the invention described in the patent claims.
Claims
As a polyribonucleotide, the polyribonucleotide is At least one 5' untranslated region; At least one 3' untranslated region; An open decoding frame operably connected to the above 5' non-translation region and 3' non-translation region and encoding a p53 analog polypeptide; and It includes a polyadenine tail located in the 3' terminal direction of the above 3' untranslated region; and At this time, the amino acid sequence of the above p53 analog polypeptide is a polyribonucleotide in which one or more variant elements selected from the group consisting of the following variant elements (A) to (G) are added to the natural p53 amino acid sequence: (A) S46E; (B) S15E, S20E, S46E; (C) G325E, F341L, L344I, Q354M; (D) E17G, D21Y, W23G, N29K, N30L; (E) L14_S15insD, T18del, S20A, D21E, W23_K24insE, L25N; (F) E180R, R181E; and (G) E180K, R181D. A polyribonucleotide according to claim 1, characterized in that the 5' untranslated region is any one sequence selected from the group consisting of SEQ ID NOs 44 to 52. A polyribonucleotide according to claim 1, characterized in that the 3' untranslated region is any one sequence selected from the group consisting of SEQ ID NOs 53 to 60. Polyribonucleotide according to any one of claims 1 to 3, wherein the amino acid sequence of the p53 analog polypeptide is a sequence having any one set of variations selected from [1] to [12] of the following natural p53 amino acid sequence: [1] S46E; [2] S15E, S20E, S46E; [3] G325E, F341L, L344I, Q354M; [4] E17G, D21Y, W23G, N29K, N30L; [5] E17G, D21Y, W23G, N29K, N30L, G325E, F341L, L344I, Q354M; [6] L14_S15insD, T18del, S20A, D21E, W23_K24insE, L25N; [7] L14_S15insD, T18del, S20A, D21E, W23_K24insE, L25N, G325E, F341L, L344I, Q354M; [8] E180R, R181E; [9] E180K, R181D; [10] E180K, R181D,G325E, F341L, L344I, Q354M; [11] E17G, D21Y, W23G, N29K, N30L, E180K, R181D; and [12] E180R, R181E,G325E, F341L, L344I, Q354M. The polyribonucleotide according to claim 1, characterized in that the polyribonucleotide is any one sequence selected from the group consisting of SEQ ID NOs 32 to 43. A polyribonucleotide according to claims 1 to 5, characterized in that the polyribonucleotide comprises one or more modified nucleotides. In claim 5, the polyribonucleotide is characterized in that at least some of the uridine residues are replaced with a modified nucleotide selected from the group consisting of pseudouridine, 1-methylpseudouridine, 5-methyluridine (m5U), 5-methoxyuridine (mo5U), and 2-thiouridine (s2U). The polyribonucleotide according to claim 1, characterized in that the polyribonucleotide is a sequence in which at least a portion of the uridine residues in any one sequence selected from the group consisting of SEQ ID NOs 32 to 43 are replaced with a modified nucleotide selected from the group consisting of pseudouridine, 1-methylpseudouridine, 5-methyluridine (m5U), 5-methoxyuridine (mo5U), and 2-thiouridine (s2U). The polyribonucleotide according to claim 1, characterized in that the polyribonucleotide further comprises a 5' cap. A composition comprising lipid nanoparticles; and mRNA embedded within the lipid nanoparticles; wherein the mRNA is the polyribonucleotide of claim 1, the lipid nanoparticles have a size of 200 nm or less, and the lipid nanoparticles contain cationic lipids, sterols, phospholipids, and polyethylene glycol modified lipids. A pharmaceutical composition for the prevention or treatment of cancer comprising the lipid nanoparticle composition of claim 10. A pharmaceutical composition according to claim 11, characterized in that the cancer is a solid tumor. A pharmaceutical composition according to claim 12, characterized in that the cancer is ovarian cancer, liver cancer, stomach cancer, or lung cancer. A pharmaceutical composition according to claim 11, characterized in that the cancer is a cancer having a p53 mutation in the cancer cells that reduces the activity of p53.
